We are live on
!
Find out more
PBM
Propel Bio Management Portfolio holdings
AUM
$159M
1-Year Est. Return
60.94%
This Fund
S&P 500
This Quarter
Est. Return
+41.22%
1 Year Est. Return
+60.94%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$172M
AUM Growth
+$51.2M
(+42%)
Cap. Flow
+$23.3M
Cap. Flow
% of AUM
13.57%
Top 10 Holdings %
Top 10 Hldgs %
82.87%
Holding
37
New
3
Increased
5
Reduced
1
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Simplify Enhanced Income ETF
HIGH
|
+$33.7M |
| 2 |
Achieve Life Sciences
ACHV
|
+$10.9M |
| 3 |
AKRO
Akero Therapeutics
AKRO
|
+$5.47M |
| 4 |
Phathom Pharmaceuticals
PHAT
|
+$3.63M |
| 5 |
APLT
Applied Therapeutics
APLT
|
+$3.31M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Plains GP Holdings
PAGP
|
+$21.9M |
| 2 |
Crinetics Pharmaceuticals
CRNX
|
+$5.87M |
| 3 |
Vanguard Short-Term Bond ETF
BSV
|
+$2.13M |
| 4 |
IBDP
iShares iBonds Dec 2024 Term Corporate ETF
IBDP
|
+$2.13M |
| 5 |
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
|
+$1.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 78.83% |
| 2 | Technology | 1.46% |
| 3 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
HELP
26
Cybin Inc
HELP
$471M
| $351K | 0.2% |
22,368
| – | – |
|
27
Agios Pharmaceuticals
AGIO
$2.14B
| – | – |
-5,792
| Closed | -$129K |
|
|
28
Vanguard Short-Term Bond ETF
BSV
$44.7B
| – | – |
-27,712
| Closed | -$2.13M |
|
|
29
Crinetics Pharmaceuticals
CRNX
$8.88B
| – | – |
-165,000
| Closed | -$5.87M |
|
30
State Street SPDR Bloomberg Investment Grade Floating Rate ETF
FLRN
$3.07B
| – | – |
-9,267
| Closed | -$283K |
|
31
Heron Therapeutics
HRTX
$92M
| – | – |
-104,195
| Closed | -$177K |
|
|
32
Plains GP Holdings
PAGP
$5.2B
| – | – |
-1,372,360
| Closed | -$21.9M |
|
33
iShares 0-5 Year Investment Grade Corporate Bond ETF
SLQD
$2.37B
| – | – |
-12,148
| Closed | -$598K |
|
|
34
State Street SPDR Portfolio Short Term Corporate Bond ETF
SPSB
$10.4B
| – | – |
-45,695
| Closed | -$1.36M |
|
|
IBDP
35
DELISTED
iShares iBonds Dec 2024 Term Corporate ETF
IBDP
| – | – |
-85,442
| Closed | -$2.13M |
|
Similar funds
OS
BDAM
OC
JF
1L
USWIA
EWA
RP
Propel Bio Management's Q1 2024 Portfolio in Review
As of Q1 2024, Propel Bio Management held 37 positions worth $172M, up 42% from $121M the previous quarter. Its ten largest holdings account for 83% of the portfolio.
Propel Bio Management deployed $23.3M of net new capital in Q1 2024, opening 3 new positions and adding to 5 existing holdings. Its largest new stake was Achieve Life Sciences: 2,453,092 shares worth $11.1M.
By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 63% a quarter earlier, followed by Technology and Energy.
On the sell side, the most notable exit was Plains GP Holdings, an estimated $21.9M sold.
- Propel Bio Management's largest Q1 2024 buy was Achieve Life Sciences: 2,453,092 shares worth $11.1M.
- Propel Bio Management added most to Simplify Enhanced Income ETF in Q1 2024, an estimated $33.7M increase.
- Propel Bio Management fully exited Plains GP Holdings in Q1 2024, selling an estimated $21.9M.
- Propel Bio Management's ten largest holdings make up 83% of its $172M portfolio in Q1 2024.
- Propel Bio Management opened 3 new positions and closed 9 in Q1 2024.
- Propel Bio Management's portfolio value rose 42% quarter-over-quarter to $172M.
Based on Propel Bio Management's 13F filing for Q1 2024, filed 13 May 2024.